| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rocket One Inc. Common Stock$1.03
+0.01 (+1.01%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
-
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.17 M
52 Week Range
-
% held by Insiders
2.89 %
% held by Institutions
3.52 %
Enterprise Value
-
Total Shares
-
Short %
29.68 %
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RKTO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RKTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RKTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RKTO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RKTO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RKTO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RKTO
Jun 3, 2026Adelina: 4702663 ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD Former U.S. Army Major General Brings Decades of National Security, Strategic Operations, and Defense Leaders
Rocket One, Inc. has appointed Major General Malcolm B. Frost (Ret.) to its Space and Defense Advisory Board. General Frost brings extensive experience in military operations and strategic planning from his nearly four-decade-long career in the U.S. Army. His appointment is expected to enhance Rocket One's development of advanced computing technologies aimed at addressing national security needs. The company is focused on creating technologies for space and defense applications while navigating significant challenges related to funding and market competition.
Read more →-RKTO
Jun 1, 2026Conf# 4700878 Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology Pioneering nanomagnetics researcher to guide development of the company's radiation-tolerant, ultra-low-
Rocket One Inc. has appointed Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for its AI nanomagnetic technology. His role is pivotal in advancing the company's development of radiation-tolerant AI chip platforms designed for space and defense applications. With his extensive expertise in nanomagnetics, Dr. Bandyopadhyay aims to translate foundational research into practical and deployable systems. This strategic appointment marks a significant transition for Rocket One as it shifts focus from launch technologies to computing solutions suitable for harsh environmental conditions.
Read more →-RKTO
May 28, 2026Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications Access to AI Developer Cloud Resources is Expecte
Rocket One Inc. has been accepted into the AMD AI Developer Program, which will provide the company with essential cloud computing resources and technical training aimed at enhancing the development of its nanomagnetic AI accelerator technologies. This partnership is expected to assist Rocket One in evaluating and refining advanced computing architectures pertinent to AI processing performance and energy efficiency. The company is focused on utilizing these resources for future applications in defense and space sectors while recognizing the significant challenges and competition it faces in these rapidly evolving areas.
Read more →-RKTO
May 27, 2026Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applicati
Hoth Therapeutics has announced its rebranding to Rocket One Inc., effective May 26, 2026, as it shifts its focus to the space economy. The new identity comes alongside an exclusive license for nanomagnetic AI chip technology suited for low-power and radiation-tolerant applications in space and defense. With a new ticker symbol 'RKTO', the company aims to address the evolving needs of the orbital economy and leverage its existing biotechnology pipelining under a subsidiary. Challenges remain, including the early-stage development of technologies and the need for significant capital to advance them.
Read more →-RKTO
May 19, 2026AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Techn
Hoth Therapeutics announced its restructuring as Rocket One Inc. to focus on the AI semiconductor market. The company has acquired exclusive rights to advanced semiconductor technology targeting energy efficiency in AI computing. This strategic shift aims to address critical infrastructure challenges in the rapidly growing AI sector while maintaining its biotechnology programs through a separate subsidiary. The restructuring was unanimously approved by the Board of Directors and signals a significant pivot toward emerging opportunities in AI infrastructure.
Read more →-RKTO
Apr 1, 2026Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
Hoth Therapeutics announced a definitive agreement to sell 2,857,144 shares at an offering price of $0.70 each, totaling approximately $2 million. A concurrent private placement involved unregistered warrants for further potential proceeds of about $2.4 million. The company plans to use the proceeds for general corporate purposes, which may support its ongoing development of innovative therapies. Closing of the offering is anticipated around April 2, 2026, subject to customary conditions.
Read more →-RKTO
Jan 16, 2026January 2026 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the me
Hoth Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing next-generation therapeutics aimed at unmet patient needs. The company highlighted its key investment programs showing clear regulatory paths and a robust pipeline across various therapeutic areas, including oncology and neurology. Hoth's lead product candidates include HT-001, which reduces skin toxicity from cancer therapies, and HT-KIT, targeting rare cancers. The company has set strategic milestones for its product candidates through 2026, demonstrating a commitment to enhancing patient quality of life.
Read more →-RKTO
Oct 14, 2025October 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the me
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapeutics that address significant unmet medical needs. The company's pipeline includes innovative treatments such as HT-001 for EGFR inhibitor-induced skin toxicity and HT-KIT for systemic mastocytosis. An ongoing study has shown promising preliminary results for HT-001, with plans for further clinical advancements slated for 2024 and beyond. However, Hoth emphasizes that its forward-looking statements involve risks and uncertainties, including regulatory challenges and market competition.
Read more →-RKTO
Jun 24, 2025HT - 001 The first therapy for EGFR inhibitor induced cutaneous toxicities Innovating for Everyone Safe Harbor Statement A significant unmet need Cancer patients on EGFR inhibitors experiencing severe dermatological side
HT - 001 is highlighted as the first topical gel developed to address cutaneous toxicities experienced by patients on EGFR inhibitors, such as those suffering from non-small cell lung cancer and other malignancies. Current management options are limited, often resulting in dose reductions or treatment cessation. Preliminary data from the ongoing Phase 2a study indicate promising outcomes, including significant reductions in skin lesions and discomfort among patients. The development of HT - 001 may represent a critical advancement for this patient population facing debilitating side effects.
Read more →-RKTO
Jun 18, 2025Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth June 18 2025 - NEW YORK, NY - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focus
Hoth Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the compliance matter officially. This achievement reflects a growing confidence in the company's strategy and pipeline, according to CEO Robb Knie. With an advancing clinical portfolio focused on various therapeutic areas, the company is optimistic about upcoming milestones and potential value creation in 2025.
Read more →-RKTO
Jun 6, 2025June 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meani
Hoth Therapeutics, a clinical-stage biopharmaceutical company, is advancing its pipeline of innovative therapeutics aimed at addressing unmet patient needs. Their lead candidate, HT-001, has shown promising efficacy in reducing skin toxicities associated with EGFR inhibitors, reflecting the company's commitment to developing impactful treatments. However, the company acknowledges various risks that could affect its forward-looking statements, including regulatory challenges and economic conditions. Hoth's strategic approach in early-stage research positions it to potentially bring breakthrough therapies to market.
Read more →-RKTO
Apr 15, 2025Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial
Hoth Therapeutics announced positive interim results from its Phase 2a clinical trial for HT-001, which aims to relieve pruritus caused by EGFR inhibitors. The initial data revealed a 50% reduction in pruritus scores by Day 21, indicating the treatment's potential benefits for patients experiencing severe itching associated with cancer therapies. The trial, which includes both open-label and randomized components, underscores Hoth's commitment to addressing unmet medical needs in oncology care.
Read more →-RKTO
Jan 24, 2025Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements New York, NY
Hoth Therapeutics, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement. This compliance was achieved as the company's stock closed above $1.00 per share for 10 consecutive business days. CEO Robb Knie expressed satisfaction with this milestone, indicating a commitment to shareholder value and corporate governance. The company is dedicated to advancing its pipeline and improving patient outcomes.
Read more →-RKTO
Nov 29, 2024December 2024 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the m
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address unmet medical needs. The company is advancing multiple products in its pipeline, including HT-001 for skin toxicities associated with EGFR inhibitors and HT-KIT for systemic mastocytosis. Recent milestones include the initiation of Phase 2a clinical trials for HT-001 and ongoing preparations for HT-KIT's IND submission. Despite its promising potential, the company acknowledges challenges such as regulatory hurdles and economic uncertainties that could impact its operations and performance.
Read more →-RKTO
Nov 20, 2024Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
Hoth Therapeutics, Inc. announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as part of its treasury strategy. The company views Bitcoin as a strong asset due to growing institutional interest and its inflation-resistant properties. CEO Robb Knie stated this decision aligns with the recent approval of Bitcoin ETFs, which has increased investor confidence in Bitcoin. However, the move comes with risks associated with Bitcoin's volatility and the challenges of implementing a new treasury strategy.
Read more →-RKTO
Mar 27, 2024Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
Hoth Therapeutics announced the exercise of warrants that will yield approximately $4.2 million in gross proceeds. The company has reduced the exercise price of existing warrants to $1.6775 per share from $5.00, encouraging immediate cash flow. New unregistered warrants for the purchase of additional shares at $1.50 each are also being issued. This transaction is expected to close around April 1, 2024 and is aimed at supporting general working capital needs.
Read more →-RKTO
Sep 13, 2023Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Hoth Therapeutics has announced a registered direct offering of 1,100,000 shares priced at $2.63 per share, totalling approximately $2.89 million. The offering is executed under Nasdaq rules and is expected to close around September 15, 2023. Proceeds will be utilized for general working capital necessities. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.
Read more →-RKTO
Dec 29, 2022Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market NEW YORK, December 29, 2022/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for t
Read more →-RKTO
Nov 9, 2022Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements NEW YORK, November 9, 2022 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market
Read more →-RKTO
Oct 26, 2022Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on
Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 NEW YORK, NY October 24, 2022 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-
Read more →-RKTO
Apr 25, 2022Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs APRIL 2022 Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning
Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs APRIL 2022 Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the "safe - harbor" provisions of the Private Securitie
Read more →-RKTO
Apr 11, 2022Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock NEW YORK, April 11, 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, d
Read more →-RKTO
Jan 4, 2022Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid in Alzheimer's Disease Significant decrease in A seen in an Alzheimer's disease mouse model after acute treatment with HT-ALZ, suppor
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid in Alzheimer's Disease Significant decrease in A seen in an Alzheimer's disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ has the potential to modify A plaque fo
Read more →-RKTO
Dec 8, 2021Hoth Therapeutics Licenses Lupus Therapeutic Back to Zyl Therapeutics Hoth to receive shares in Zyl and potential future sales royalties
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zyl Therapeutics Hoth to receive shares in Zyl and potential future sales royalties December 8, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing ne
Read more →-RKTO
Sep 1, 2021Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs SEPTEMBER 2021 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the m
Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs SEPTEMBER 2021 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the meaning of the "safe - harbor" provisions of the Private Sec
Read more →-RKTO
Jun 28, 2021Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis T he primary objectives were achieved in cohort one BioLexa was well-to
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis objectives were achieved in cohort one BioLexa was well-tolerated with no treatment related adverse events Cohort 2 patient sc
Read more →-RKTO
May 24, 2021Introduction to HT - KIT an mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell - Derived Cancers Safe Harbor Statement This presentation contains "forward - looking statements" within the me
Introduction to HT - KIT an mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell - Derived Cancers Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the "safe - harbor" provisions of the Private Secu
Read more →-RKTO
Mar 8, 2021Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Announces $15 Million Private Placement Priced At-the-Market NEW YORK, March 8, 2021/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain
Read more →-RKTO
Jan 4, 2021Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections License Covers Novel Molecul
Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections Covers Novel Molecular Entity Developed by the Walter Reed Army Institute of Research HT-0
Read more →-RKTO
Sep 21, 2020HOTH THERAPEUTICS ENTERS INTO SPONSORED RESEARCH AGREEMENT FOR ON-THE-GO COVID-19 TESTING DEVICE Company will Partner with the George Washington University on R&D for their Licensed Smartphone-Based Direct Virus Sensing
HOTH THERAPEUTICS ENTERS INTO SPONSORED RESEARCH AGREEMENT FOR ON-THE-GO COVID-19 TESTING DEVICE Company will Partner with the George Washington University on R&D for their Licensed Smartphone-Based Direct Virus Sensing System NEW YORK , Sept. 21, 2020 /PRNewswire/ -- Hoth T
Read more →-RKTO
Aug 31, 2020Hoth Therapeutics Appoints Dr. Stefanie Johns, Ph.D., as Chief Scientific Officer
Hoth Therapeutics Appoints Dr. Stefanie Johns, Ph.D., as Chief Scientific Officer NEW YORK, NY August 31, 2020 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief S
Read more →-RKTO
Aug 10, 2020Hoth Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device Project Originally Funded at George Washington University by COVID-19 Technology Maturation Grant No Sali
Therapeutics Licenses Intellectual Property to Develop Real-time, Breath-Based COVID-19 Mobile Testing Device Originally Funded at George Washington University COVID-19 Technology Maturation Grant Saliva or Blood Needed to Allow Public Health Professionals to Immediately Dia
Read more →-RKTO
Jul 31, 2020Hoth Therapeutics' Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases Hoth to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields inc
Therapeutics' Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields including Oncology YORK, NY July 31, 2020 -- Hoth Therapeutics, Inc. (N
Read more →-RKTO
Jun 30, 2020Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment Hoth has exclusive license to this novel peptide COVID-19 therapeutic
Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment has exclusive license to this novel peptide COVID-19 therapeutic June 30, 2020 / PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a s
Read more →-RKTO
May 21, 2020Hoth Announces Pricing of Public Offering of Shares of Common Stock
Hoth Announces Pricing of Public Offering of Shares of Common Stock May 21, 2020 /PR Newswire/ Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of
Read more →-RKTO
May 21, 2020Hoth Announces Proposed Public Offering of Common Stock
Hoth Announces Proposed Public Offering 21, 2020 /PR Newswire/ Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company exp
Read more →-RKTO
Apr 17, 2020Hoth Therapeutics Announces Additions to its Board of Directors
Hoth Therapeutics Announces Additions to its Board of Directors NEW YORK, NY April 17, 2020/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to
Read more →-RKTO
Mar 23, 2020Hoth Therapeutics Announces Agreement to Joint Development For a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19) The SAV technology has been exclusively licensed from Massachusett
Therapeutics Announces Agreement to Joint Development For a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19) has been exclusively licensed from Massachusetts General Hospital Preclinical development to be undertaken in conjunction with
Read more →-RKTO
Oct 21, 2019(NASDAQ: HOTH) Fall 2019 Corporate Presentation
(NASDAQ: HOTH) Fall 2019 Corporate Presentation Disclaimer and Safe Harbor Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the "safe - harbor" provisions of the Private Securities Litigation Reform Act of 1995 . These stateme
Read more →-RKTO
Sep 4, 2019Hoth Therapeutics, Inc. Issues Letter to Shareholders
Therapeutics, Inc. Issues Letter to Shareholders YORK, Sept. 4, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis
Read more →-RKTO
Aug 23, 2019Hoth Therapeutics and Zyl Therapeutics
Hoth Therapeutics and Zyl Therapeutics Zyl and Hoth Therapeutics Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus Zyl 's xerogel-derived delivery platform to be used to topically deliver the drug candidate NEW YORK, NY August 21, 2019/PR Newswire/ Hoth
Read more →-RKTO
Apr 29, 2019May 2019 Corporate Presentation
May 2019 Corporate Presentation Disclaimer and Safe Harbor Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the "safe - harbor" provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identifi
Read more →-RKTO
Feb 15, 2019Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol "HOTH"
Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol "HOTH" NEW YORK, NY, February 15, 2019 /GlobeNewswire/ Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on
Read more →Competitive Position
How RKTO ranks across every disease it competes inCompetitive Position is a premium feature
See how RKTO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial